SPRY4 functions as an inhibitor of the receptor-transduced mitogen-activated protein kinase (MAPK) signaling pathway . It is positioned upstream of RAS activation and impairs the formation of active GTP-RAS . By doing so, SPRY4 suppresses the epidermal growth factor receptor (EGFR)-transduced MAPK signaling pathway . This inhibition is crucial for regulating cellular responses to growth signals and maintaining cellular homeostasis.
The MAPK/ERK signaling pathway, regulated by SPRY4, is one of the most widespread regulatory mechanisms in eukaryotic cell biology . Dysregulation of this pathway can lead to various diseases, including cancer. Therefore, SPRY4’s role as a negative regulator is vital for preventing uncontrolled cell proliferation and tumorigenesis.
Human recombinant SPRY4 is used in research to study its inhibitory effects on MAPK signaling and its potential therapeutic applications. Understanding SPRY4’s function and regulation can provide insights into developing targeted therapies for diseases associated with aberrant RTK signaling.